Sara Hurvitz, MD, FACP, Senior Vice President and director of the Clinical Research at Fred Hutchinson Cancer Center, speaks to SABCS Program Director Kate Lathrop, MD, about the primary analysis of HER2CLIMB-02: Tucatinib and Trastuzumab Emtansine for HER2-Positive Metastatic Breast Cancer.
▷ Estimated Read Time:
1–2 minutes
SABCS Snippets: Primary analysis of HER2CLIMB-02
Connect with thousands of basic and translational scientists, multidisciplinary clinicians, regulatory and pharmaceutical partners, survivors, and patient advocates at the 49th annual San Antonio Breast Cancer Symposium. Complete your registration by Friday, September 25, to take advantage of discounted early registration rates.
Share:
Recent Posts
Recent Posts
-
December 15, 2025
-
December 15, 2025
-
December 15, 2025
-
December 15, 2025
